Latest Industry Insights

Technology Networks recently interviewed Anthony V. Lemmo, to learn how rapid antigen tests work, how they compare to PCR tests and how they can be used to help slow the spread of SARS-CoV-2.

Western blotting has been a core technique in molecular biology for many years, however, optimization and reproducibility can be problematic. We spoke to Dr Alexandre Lucas about the automation of western blotting and the difference this advance is making to research.

180 Life Sciences is exploring the use of synthetic cannabidiol (CBD) analogs as a treatment strategy for inflammation and pain, and conducting clinical research focused on repurposing anti-tumor necrosis factor across different fibrotic conditions. Technology Networks recently spoke with Dr James Woody, chief executive officer at 180 Life Sciences, to find out more about the company's research and development pipeline.

Technology Networks recently interviewed Viswa Colluru, founder and CEO of Enveda Biosciences, to find out how the company is “harnessing the complexity of the natural world to tackle today’s biggest healthcare challenges”.

In this interview, Dr Andreas Bergmann discusses how the quantification of two pathway-specific biomarkers can support the diagnosis, monitoring and treatment of sepsis patients.

Liquid chromatography has proven to be an invaluable tool in analytical labs. However, despite being a “mature” technique, there are still some areas that prove problematic, leading to suboptimal results. One such area is the loss of analytes during the chromatographic process, but design innovations are aiming to overcome this problem.

Arquer Diagnostics is developing non-invasive tests for diagnosing and monitoring cancer, using patented technology to detect the cancer biomarker MCM5. Technology Networks had the pleasure of speaking with Nadia Whittley, Chief Executive Officer of Arquer Diagnostics, to learn more about the study and its significance.

Verve Therapeutics is utilizing two of the biggest scientific breakthroughs of the twenty-first century – DNA sequencing and genome editing – to design a one-time treatment for lowering cholesterol.

2020 was an important year for proteomics. The COVID-19 global pandemic cast a spotlight on the field's clinical utility in the fight against a public health crisis, from which there are many lessons to be drawn that will undoubtedly influence the landscape of the field for years to come. Technology Networks spoke with Rohan Thakur, executive vice president of Life Sciences Mass Spectrometry at Bruker Daltonics, to discuss the current state-of-play in proteomics.

SynDevRx is working to address the unmet medical need in the field of metabo-oncology by developing treatments for cancer patients who are overweight or have systemic metabolic dysfunction. Technology Networks recently spoke with SynDevRx's Jim Shanahan, to explore the impact of metabolic dysfunction on treatment outcomes and learn more about the company’s lead compound SDX-7320.